Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
AssigneeIcahn School of Medicine at Mount Sinai
InventorsWillem MULDER, Jordi OCHANDO, Zahi FAYAD, Mounia BRAZA, Raphael DUIVENVOORDEN, Francois FAY
Life of this patent
Estimating the term…
Abstract
Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.
Claims27
A method of inducing immune tolerance comprising administering to a patient an effective amount of (i) a composition comprising a high-density lipoprotein-derived nanoparticle (HDL) which comprises an mTOR inhibitor.
-16. (canceled)
A method for prophylaxis of organ or tissue rejection, the method comprising the step of administering to a patient in need thereof an effective amount of a composition comprising a high-density lipoprotein-derived nanoparticle (HDL) which comprises an mTOR inhibitor.
-25. (canceled)
A composition comprising a high-density lipoprotein-derived nanoparticle (HDL) which comprises an m-TOR inhibitor.
-38. (canceled)
-59. (canceled)
A composition comprising a high-density lipoprotein-derived nanoparticle (HDL) which comprises rapamycin or a pharmaceutically acceptable salt, solvate, poly-morph, tautomer or prodrug thereof, formulated as rapamycin nanoparticle (rapamycin-HDL) and wherein the HDL comprises 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) and 1-myristoyl-2-hydroxy-sn-glycero-phosphocholine (MHPC), and wherein the weight ratio of DMPC to MHPC is about 3:1.
Dependencies are inferred from the claim text.